Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
1990 1
1991 4
1992 5
1993 1
1994 1
1995 2
1996 3
1997 2
1998 2
2004 1
2008 4
2009 4
2010 1
2011 5
2012 7
2013 3
2014 7
2015 5
2016 6
2017 5
2018 5
2019 6
2020 5
2021 5
2022 9
2023 5
2024 3

Text availability

Article attribute

Article type

Publication date

Search Results

99 results

Results by year

Filters applied: . Clear all
Page 1
Epcoritamab, a Novel, Subcutaneous CD3xCD20 Bispecific T-Cell-Engaging Antibody, in Relapsed or Refractory Large B-Cell Lymphoma: Dose Expansion in a Phase I/II Trial.
Thieblemont C, Phillips T, Ghesquieres H, Cheah CY, Clausen MR, Cunningham D, Do YR, Feldman T, Gasiorowski R, Jurczak W, Kim TM, Lewis DJ, van der Poel M, Poon ML, Cota Stirner M, Kilavuz N, Chiu C, Chen M, Sacchi M, Elliott B, Ahmadi T, Hutchings M, Lugtenburg PJ. Thieblemont C, et al. Among authors: clausen mr. J Clin Oncol. 2023 Apr 20;41(12):2238-2247. doi: 10.1200/JCO.22.01725. Epub 2022 Dec 22. J Clin Oncol. 2023. PMID: 36548927 Free PMC article. Clinical Trial.
Dose escalation of subcutaneous epcoritamab in patients with relapsed or refractory B-cell non-Hodgkin lymphoma: an open-label, phase 1/2 study.
Hutchings M, Mous R, Clausen MR, Johnson P, Linton KM, Chamuleau MED, Lewis DJ, Sureda Balari A, Cunningham D, Oliveri RS, Elliott B, DeMarco D, Azaryan A, Chiu C, Li T, Chen KM, Ahmadi T, Lugtenburg PJ. Hutchings M, et al. Among authors: clausen mr. Lancet. 2021 Sep 25;398(10306):1157-1169. doi: 10.1016/S0140-6736(21)00889-8. Epub 2021 Sep 8. Lancet. 2021. PMID: 34508654 Clinical Trial.
[Isoniazid-inducedtoxic hepatitis].
Kristensen KL, Nordholm AC, Clausen MR, Katzenstein TL. Kristensen KL, et al. Among authors: clausen mr. Ugeskr Laeger. 2021 Feb 8;183(6):V10200770. Ugeskr Laeger. 2021. PMID: 33570026 Free article. Danish.
Metabolomics to Explore Impact of Dairy Intake.
Zheng H, Clausen MR, Dalsgaard TK, Bertram HC. Zheng H, et al. Among authors: clausen mr. Nutrients. 2015 Jun 17;7(6):4875-96. doi: 10.3390/nu7064875. Nutrients. 2015. PMID: 26091233 Free PMC article. Review.
Trichinella infection and clinical disease.
Clausen MR, Meyer CN, Krantz T, Moser C, Gomme G, Kayser L, Albrectsen J, Kapel CM, Bygbjerg IC. Clausen MR, et al. QJM. 1996 Aug;89(8):631-6. doi: 10.1093/qjmed/89.8.631. QJM. 1996. PMID: 8935484 Review.
Severity and 90-day survival of SARS-CoV-2 infection among patients with haematological disorders.
Glenthøj A, Jakobsen LH, Bjørn ME, Poulsen CB, Sengeløv H, Severinsen MT, Qvist K, Overgaard UM, Ahmad SA, Rewes A, Mølle I, Strandholdt CN, Kodahl AR, Ryg J, Brieghel C, Johansen IS, Kannik K, Jensen-Fangel S, Wiese L, Kirk O, Clausen MR, Helleberg M, Frederiksen H. Glenthøj A, et al. Among authors: clausen mr. Acta Oncol. 2022 Apr;61(4):500-504. doi: 10.1080/0284186X.2022.2026464. Epub 2022 Jan 17. Acta Oncol. 2022. PMID: 35038967 No abstract available.
Cardiovascular diseases in elderly survivors of diffuse large B-cell lymphoma: a Danish population-based cohort study.
Juul MB, Jelicic J, Anru PL, Engberg H, Hammershøj Jensen P, Kristensen HB, Baech J, Clausen MR, Gang AO, Munksgaard L, El-Galaly TC, Frederiksen H, Stauffer Larsen T. Juul MB, et al. Among authors: clausen mr. Leuk Lymphoma. 2022 Sep;63(9):2074-2083. doi: 10.1080/10428194.2022.2064982. Epub 2022 Apr 18. Leuk Lymphoma. 2022. PMID: 35437098
99 results